Den europeiske union - estisk - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

Den europeiske union - estisk - EMA (European Medicines Agency)

novartis europharm limited - erenumab - migreenihäired - valuvaigistid - aimovig on näidustatud migreeni profülaktika täiskasvanutel, kellel on vähemalt 4 migreen päeva kuus, kui algatamise ravi aimovig.

Den europeiske union - estisk - EMA (European Medicines Agency)

novartis europharm limited  - brolucizumab - märg macula degeneration - oftalmoloogilised vahendid - beovu on näidustatud täiskasvanute raviks neovascular (märg) vanusega seotud makuladegeneratsiooni (amd).

Den europeiske union - estisk - EMA (European Medicines Agency)

novartis europharm limited  - onasemnogene abeparvovec - lihase atroofia, spinaalne - muud lihas-skeleti süsteemi häirete ravimid - zolgensma on näidustatud ravi:patsiendid, kellel on 5q seljaaju lihaste atroofia (sma) koos bi-allelic mutatsioon smn1 geeni-ja kliinilise diagnoosi akti liik 1, orpatients koos 5q sma koos bi-allelic mutatsioon smn1 geeni-ja kuni 3 koopiad smn2 geenide.

Den europeiske union - estisk - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - ravimid hingamisteede obstruktiivsete haiguste, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Den europeiske union - estisk - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Den europeiske union - estisk - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Den europeiske union - estisk - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - aneemia, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Den europeiske union - estisk - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipiidi modifitseerivad ained - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Den europeiske union - estisk - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.